Company Filing History:
1 out of 1 
1 out of 50 
1 out of 5 Years Active: 2002-2025
Title: Paolo Dellabona: Innovator in Immunotherapy
Introduction
Paolo Dellabona is a prominent inventor based in Milan, Italy. He has made significant contributions to the field of immunotherapy, particularly in the development of T cell receptors (TCRs) for therapeutic applications. With a total of 2 patents, his work focuses on innovative methods for treating hematological disorders and tumors.
Latest Patents
Dellabona's latest patents include a TCR with antigenic specificity for CD1c molecules associated with self-lipids, particularly mLPA or its derivatives. This invention encompasses various applications, including polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions. The patent also details the uses of this TCR in the treatment and prevention of hematological disorders. Another significant patent describes a method for producing activated tumor-specific T cells. This method involves co-cultivating tumor cells from a patient with their T cells, utilizing fusion proteins to enhance the activation process. The efficiency and simplicity of this method mark a notable advancement in tumor treatment.
Career Highlights
Throughout his career, Paolo Dellabona has worked with notable organizations, including Science Park Raf S.p.a. and Ospedale San Raffaele S.r.l. His experience in these institutions has allowed him to refine his research and contribute to groundbreaking advancements in immunotherapy.
Collaborations
Dellabona has collaborated with esteemed colleagues such as Giulia Casorati and Claudia De Lalla. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to significant scientific breakthroughs.
Conclusion
Paolo Dellabona's contributions to immunotherapy through his patents and collaborations highlight his role as a leading inventor in the field. His innovative approaches to T cell activation and treatment methods continue to pave the way for advancements in medical science.